肿瘤细胞治疗研究
英文原题：Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.
总缓解率为100%，其中12例（67%）达到完全缓解（CR）。
细胞毒性皮肤T细胞淋巴瘤（CTCL）是一组异质性T细胞淋巴瘤，预后各异，且尚无标准治疗方案。我们纳入了2015年至2024年间在华盛顿大学/弗雷德·哈钦森癌症中心接受至少1剂普拉曲沙治疗的原发性皮肤CD8+侵袭性嗜表皮细胞毒性T细胞淋巴瘤（CD8+ PCAETL）、原发性皮肤γδ T细胞淋巴瘤（PCGDTL）和皮下脂膜炎样T细胞淋巴瘤（SPTCL）患者。18例患者符合标准，其中3例为CD8+ PCAETL，6例为PCGDTL，9例为SPTCL。既往系统性治疗的中位数为1（范围，0-4），普拉曲沙治疗的中位持续时间为14（范围，8-43）周。总缓解率为100%，其中12例（67%）达到完全缓解（CR）。中位无进展生存期和总生存期分别为5.6个月和未达到。在达到CR的患者中，中位缓解持续时间为22个月。在中位随访45个月时，6例（33%）患者仍处于持续缓解状态。这项回顾性分析首次评估了普拉曲沙在这一侵袭性疾病人群中的疗效，证明其有效性并与细胞毒性CTCL的持久缓解相关。
Cytotoxic cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of T-cell lymphomas with variable prognoses and no standard of care. We identified patients with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (CD8+ PCAETL), primary cutaneous γδ T-cell lymphoma (PCGDTL), and subcutaneous panniculitis-like T-cell lymphoma (SPTCL), who were treated with ≥1 dose of pralatrexate between 2015 and 2024 at the University of Washington/Fred Hutchinson Cancer Center. Eighteen patients met criteria, 3 with CD8+ PCAETL, 6 with PCGDTL, and 9 with SPTCL. The median number of prior systemic therapies was 1 (range, 0-4), and the median pralatrexate treatment duration was 14 (range, 8-43) weeks. The overall response rate was 100%, with 12 (67%) achieving complete response (CR). Median duration of progression-free survival and overall survival was 5.6 months and not reached, respectively. Among patients who achieved CR , the median response duration was 22 months. At a median follow-up of 45 months, 6 (33%) patients remain in sustained remission. This retrospective analysis is the first to evaluate pralatrexate's efficacy in this aggressive disease population, demonstrating its effectiveness and association with durable responses in cytotoxic CTCL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
